StockData

CRISPR Therapeutics vs Precision BioSciences

CRSP and DTIL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRSP and DTIL compare

CRISPR Therapeutics is the larger company, worth 20 times as much as Precision BioSciences ($3.9B against $195M).

Precision BioSciences grew revenue faster over the last twelve months (3473% versus −64.8% for CRISPR Therapeutics).

Precision BioSciences keeps more of each dollar of sales as profit, with a net margin of −117% compared with −3369% at CRISPR Therapeutics.

CRISPR Therapeutics scores higher on the StockData Score (8 against 4 for Precision BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRSPDTIL
Size and price
Market cap$3.9B$195M
Share price$40.15$7.05
Change, 1 year−23.6%19.9%
Change, 5 years−49.0%−97.4%
Beta (5Y)1.59−0.53
Employees39368
StockData Score
Total score8 (better)4
Valuation score00
Growth score12 (better)
Performance score2 (better)1
Health score5 (better)1
Dividend score00
Valuation
P/S290×4.3× (better)
P/B2.2× (better)4.3×
FCF yield−9.6% (better)−26.7%
Fair value–$4.46
Margin of safety–−58.2%
Growth
Revenue growth (TTM)−64.8%3473% (better)
Revenue growth, 5Y average37.3% (better)7.1%
Profitability
Operating margin−3990%−80.8% (better)
Net margin−3369%−117% (better)
FCF margin−2773%−115% (better)
Return on equity−26.1% (better)−133%
Financial health
Debt / equity0.00–
Interest coverage–−27.6×
Current ratio17.85 (better)12.82
Altman Z-score1.79 (better)−4.78
Piotroski F-score22
Dividends and buybacks
Buyback yield−10.0%–
Shareholder yield−10.0%0.00% (better)
Ownership
Held by institutions78.9%64.0%
Held by insiders2.7%3.0%
Insider net buying, 12 months−$17.9M−$396K (better)
Short interest, % of float18.3%7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.